Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C

摘要: The present invention has determined that exogenously added glycosylceramide (GlcCer) and other neutral glycolipids such as the homologous Glc-containing globotriaosylceramide (Gb3Cer), dose-dependently prolonged clotting times of normal plasma in presence but not absence APC:protein S, indicating GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. In studies using purified proteins, inactivation factor Va by S was enhanced alone GlcCer, globotriaosylceramide, lactosylceramide, galactosylceramide multicomponent vesicles containing phosphatidylserine phosphatidylcholine. Thus, provides Gb3Cer, cofactors contribute to antithrombotic activity pathway. also a deficiency is risk for thrombosis. Methods are provided determine individuals at thrombosis, methods treatment well screening factors from glycolipids.